Glomerulonephritis fellow 2023-2024 @McMasterU. Associate program director @GlomCon. Interested in glomerular diseases and kidney disease in pregnancy.
Joined December 2013
- Tweets400
- Following405
- Followers1.6K
- Likes1.2K
I had the honor of presenting our work at ASN kidney week 2026 in Denver. Thank you to everyone who stopped by. @ASNKidney #kidneywk
Sara Almutar retweeted
👇🏽Hot off the press at @NDTsocial “C5 inhibition for the Renal TMA induced by cancer therapy”! Strong work by @MBarbarini and team @MayoClinicNeph ! @MayoCancerCare @MayoClinic 👇🏽free link onconephrology
academic.oup.com/ndt/advance…
Sara Almutar retweeted
🎉 Our paper "Delphi Consensus Framework for Glomerular Disease Centers of Excellence" is out in @KIReports @GlomCon
sciencedirect.com/science/ar…
A great discussion with Dr. Ali Mehdi from @CleClinicKidney on the evolving IgA nephropathy treatment landscape.
Despite the advances, many questions remain! @glomconarabia @GlomCon
Sara Almutar retweeted
Our comprehensive, thorough, and up-to-date review on B-Cell modulation in Immunoglobulin A Nephropathy is out. @DanaRizk1 @UAB_NRTC @RMANewMexico
frontiersin.org/journals/imm…
Sara Almutar retweeted
We are excited to host another session in the GlomCon Arabia Seminar Series tomorrow Friday, October 9, 2026
This session will feature an expert presentation by Dr. Ali Mehdi “IgA Nephropathy: Where We Are and Where We Are Going”
Meeting details:
glomcon.zoom.us
Meeting ID: 884 4208 1901
Passcode: 100499
@GlomCon @glomconarabia #NephrologyEducation #MedicalCommunity #GlobalMedicine @CleClinicKidney
Sara Almutar retweeted
C3G Glomerulopathy: Mechanistic Targets 🎯 of Potential Novel Therapies from @goKDIGO
#Nephpearls
👉 kdigo.org/infographics/ – at Riverside, IL
Sara Almutar retweeted
Treatment with maximally tolerated RAASi alone does not sufficiently slow the rate of eGFR decline in high-risk patients with IgA nephropathy #IgAN, leaving patients at risk of ESKD ca. 2026 from @DrAnjayRastogi @asnpublications
#Nephpearls
📌 These findings underscore the need for disease-modifying therapies capable of effectively preserving kidney function, particularly in this predominantly young patient population
👉 pubmed.ncbi.nlm.nih.gov/4258… – at Grapevine, TX
Sara Almutar retweeted
🚨 Latest news in #IgAN!
Sefaxersen achieved statistically significant and clinically meaningful reductions in proteinuria vs placebo at week 37 in the phase III IMAgINATION study.
By inhibiting hepatic production of complement factor B, sefaxersen targets a key driver of complement activation in IgA nephropathy 🧬
#Nephrology #Complement #IgAN #GlomerularDiseases #ClinicalTrials
🔗 roche.com/media/releases/med…
Sara Almutar retweeted
We are excited to host another session in the GlomCon Arabia Seminar Series on Friday, September 18, 2026.
This session will feature an expert presentation by Dr. Hala Kfoury Kassouf, MD, EMBA titled “Infection-related Kidney Injury: Mechanisms, Implications, and Pathological Insights”
Meeting details:
glomcon.zoom.us
Meeting ID: 884 4208 1901
Passcode: 100499
lnkd.in/d5Ta7sQg
We invite you to join us for this informative session and connect with colleagues from around the world!
#GlomCon #GlomConArabia #NephrologyEducation #MedicalCommunity #GlobalMedicine
Sara Almutar retweeted
Complement in Kidney Disease: Core Curriculum 2026
@AJKDonline
ajkd.org/article/S0272-6386%…
Sara Almutar retweeted
Last week kicked off another year of the @GlomCon Glomerular Disease fellowship program 🎉
Watching it grow each year; more competitive applicants, close to 200 fellows educated annually; is a testament to the amazing community we’ve built: our #faculty, #instructors, program directors & associates.
Grateful doesn’t even cover it. 💙
#GlomCon #Nephrology #Education
@Nephronpower @jogameiro @s_almutar @poyanmehr
So honored to be part of this amazing community and to serve as an associate program director!
Very grateful for this opportunity and excited for another wonderful chapter of learning and growth! @GlomCon ✨
Last week kicked off another year of the @GlomCon Glomerular Disease fellowship program 🎉
Watching it grow each year; more competitive applicants, close to 200 fellows educated annually; is a testament to the amazing community we’ve built: our #faculty, #instructors, program directors & associates.
Grateful doesn’t even cover it. 💙
#GlomCon #Nephrology #Education
@Nephronpower @jogameiro @s_almutar @poyanmehr
Sara Almutar retweeted
A systematic review takes one to two years. Very little of that time goes to thinking. It goes to moving citations between disconnected tools.
We built CoreSR to strip that out and return the reviewer's time to judgment.
youtube.com/@CoreSR
coresr.ai/
Sara Almutar retweeted
In this article we review predictors of response to sparsentan in patients with IgA nephropathy. Higher systolic BP and hematuria at baseline increased likelihood of response to therapy at 9months! @AnilaCara @mvargas07 @fervenzaf @CristianJuanet
academic.oup.com/ckj/advance…
Sara Almutar retweeted
Ten years ago, GlomCon started with a name.
Since then, that name has grown into a global community connecting clinicians, researchers, trainees, and patients across the world.
Sharing knowledge. Learning from one another. Collaborating across borders. Working toward better kidney care, together.
Today, we’re giving that story a new look.
A new chapter for a community built on connection, knowledge, and purpose.
Ten years of connection. One mission forward.
#GlomCon #Nephrology #KidneyCare #MedicalEducation
Sara Almutar retweeted
As August comes to an end, I’m looking back at one of the highlights of my year: #GlomConHawaii.
Brilliant and humble experts in glomerular and rare kidney diseases, meaningful discussions about the future of nephrology, all in one of the most peaceful places on Earth.
A pleasure moderating sessions on the future of glomerular diseases and plasmapheresis. Thank you for the invitation!
@poyanmehr @SaynaNorouzi @Nephronpower @DanaRizk1 @kidneybiz @GlomCon
Sara Almutar retweeted
Pre-transplant genetic testing in patients with FSGS.
We test both the recipient and the donor if the donor is related to the recipient. 👌🏾 @NadaAlachkar @glomconarabia
Sara Almutar retweeted
Join GlomCon this Sunday for the next GlomCon Sunday Seminar.
Immune checkpoint inhibitor AIN
Presented by Meghan Sise, MD, MS
Sunday, August 16, 2026
8:00 AM PDT
Zoom ID: 817 4374 4653
Passcode: 202122
Register to join live: glomcon.org
#GlomCon #Nephrology #KidneyDisease #MedicalEducation #KidneyResearch
